CN113661158A - 新型水杨酸衍生物、其药学上可接受的盐、其组合物及其使用方法 - Google Patents

新型水杨酸衍生物、其药学上可接受的盐、其组合物及其使用方法 Download PDF

Info

Publication number
CN113661158A
CN113661158A CN201980089744.6A CN201980089744A CN113661158A CN 113661158 A CN113661158 A CN 113661158A CN 201980089744 A CN201980089744 A CN 201980089744A CN 113661158 A CN113661158 A CN 113661158A
Authority
CN
China
Prior art keywords
cancer
compound
group
pharmaceutically acceptable
stat3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980089744.6A
Other languages
English (en)
Chinese (zh)
Inventor
帕特里克·托马斯·贡宁
西亚瓦什·艾哈迈尔
戴维·罗萨
加里·廷
穆卢·格勒图
朴智星
埃尔文·D·德·阿劳约
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jane Pixar Co ltd
University of Toronto
Original Assignee
Jane Pixar Co ltd
University of Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jane Pixar Co ltd, University of Toronto filed Critical Jane Pixar Co ltd
Publication of CN113661158A publication Critical patent/CN113661158A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201980089744.6A 2018-12-21 2019-12-20 新型水杨酸衍生物、其药学上可接受的盐、其组合物及其使用方法 Pending CN113661158A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862783741P 2018-12-21 2018-12-21
US62/783,741 2018-12-21
PCT/CA2019/051884 WO2020124262A1 (en) 2018-12-21 2019-12-20 New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof

Publications (1)

Publication Number Publication Date
CN113661158A true CN113661158A (zh) 2021-11-16

Family

ID=71100034

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980089744.6A Pending CN113661158A (zh) 2018-12-21 2019-12-20 新型水杨酸衍生物、其药学上可接受的盐、其组合物及其使用方法

Country Status (6)

Country Link
US (1) US20220089531A1 (https=)
EP (1) EP3898582A4 (https=)
JP (1) JP2022515248A (https=)
CN (1) CN113661158A (https=)
CA (1) CA3124267A1 (https=)
WO (1) WO2020124262A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3174623A1 (en) * 2020-03-05 2021-09-10 Janpix, Ltd. Stat inhibitory compounds and compositions
EP4114371A4 (en) * 2020-03-05 2024-04-17 Centessa Pharmaceuticals (UK) Limited ALPHA-SUBSTITUTED STAT INHIBITORS AND COMPOSITIONS THEREOF
TW202227398A (zh) * 2020-09-04 2022-07-16 英商詹皮克斯有限公司 Stat抑制性化合物及組合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090069420A1 (en) * 2006-05-19 2009-03-12 H. Lee Moffitt Cancer Center & Research Institute Small molecule inhibitors of STAT3 with anti-tumor activity
CN102219755A (zh) * 2011-05-05 2011-10-19 南京大学 Stat3的小分子选择性抑制剂及其制备方法和应用
CN103608010A (zh) * 2010-08-02 2014-02-26 中央佛罗里达大学研究基金公司 作为stat蛋白的抑制剂的取代的2-羟基-4-(2-(苯基磺酰氨基)乙酰氨基)苯甲酸类似物
US20150158894A1 (en) * 2012-05-25 2015-06-11 The Governing Council Of The University Of Toronto Salicyclic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US20150259366A1 (en) * 2012-10-30 2015-09-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stat3 dimerization inhibitors
CN106458873A (zh) * 2014-05-30 2017-02-22 多伦多大学管理委员会 磺酰胺化合物和它们作为stat5抑制剂的用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090069420A1 (en) * 2006-05-19 2009-03-12 H. Lee Moffitt Cancer Center & Research Institute Small molecule inhibitors of STAT3 with anti-tumor activity
CN103608010A (zh) * 2010-08-02 2014-02-26 中央佛罗里达大学研究基金公司 作为stat蛋白的抑制剂的取代的2-羟基-4-(2-(苯基磺酰氨基)乙酰氨基)苯甲酸类似物
CN102219755A (zh) * 2011-05-05 2011-10-19 南京大学 Stat3的小分子选择性抑制剂及其制备方法和应用
US20150158894A1 (en) * 2012-05-25 2015-06-11 The Governing Council Of The University Of Toronto Salicyclic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
CN105120854A (zh) * 2012-05-25 2015-12-02 多伦多大学管理委员会 新水杨酸衍生物、其药学上可接受的盐、其组合物以及其使用方法
US20150259366A1 (en) * 2012-10-30 2015-09-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stat3 dimerization inhibitors
CN106458873A (zh) * 2014-05-30 2017-02-22 多伦多大学管理委员会 磺酰胺化合物和它们作为stat5抑制剂的用途

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ABBARNA A. CUMARASWAMY等: "Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein", 《ACS MED. CHEM. LETT.》 *
BETTINA WINGELHOFER等: "Pharmacologic inhibition of STAT5 in acute myeloid leukemia", 《LEUKEMIA》 *
BRENT D. G. PAGE等: "Inhibiting Aberrant Signal Transducer and Activator of Transcription Protein Activation with Tetrapodal, Small Molecule Src Homology 2 Domain Binders: Promising Agents against Multiple Myeloma", 《J. MED. CHEM.》 *
ELVIN D.DE ARAUJO等: "High-throughput thermofluor-based assays for inhibitor screening of STAT SH2 domains", 《JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS》 *
MURALI K. URLAM等: "Development of new N-arylbenzamides as STAT3 dimerization inhibitors", 《MED. CHEM. COMMUN.》 *
STEVEN FLETCHER等: "Disruption of Transcriptionally Active Stat3 Dimers with Non-phosphorylated, Salicylic Acid-Based Small Molecules: Potent in vitro and Tumor Cell Activities", 《CHEMBIOCHEM》 *
XIAOLEIZHANG等: "A novel small-molecule disrupts Stat3 SH2 domain–phosphotyrosine interactions and Stat3-dependent tumor processes", 《BIOCHEMICAL PHARMACOLOGY》 *
俞丽芬等: "信号传导及转录活化因子STAT与消化系统疾病的关系", 《世界华人消化杂志》 *
叶霁青等: "小分子IL-6/STAT3信号通路抑制剂", 《化学进展》 *

Also Published As

Publication number Publication date
US20220089531A1 (en) 2022-03-24
EP3898582A4 (en) 2022-08-24
JP2022515248A (ja) 2022-02-17
CA3124267A1 (en) 2020-06-25
WO2020124262A1 (en) 2020-06-25
EP3898582A1 (en) 2021-10-27

Similar Documents

Publication Publication Date Title
JP6543366B2 (ja) 新しいサリチル酸誘導体、薬学上許容可能なその塩、その組成物及びその使用方法
KR101717098B1 (ko) 디글리시드 에테르 유도체 치료법 및 이의 사용 방법
KR102288648B1 (ko) 히스톤 데메틸라제 억제제로서의 치환된 (e)-n′-(1-페닐에틸리덴)벤조하이드라지드 동족체
JP6122006B2 (ja) ヒストン脱メチル化酵素阻害剤としての、置換された（ｅ）−ｎ’−（１−フェニルエチリデン）ベンゾヒドラジド類似体
WO2025011568A1 (zh) 用作shp2抑制剂的杂环化合物、包含其的药物组合物及其制备方法和用途
WO2007149782A2 (en) Selective inhibitors for transferases
CN113661158A (zh) 新型水杨酸衍生物、其药学上可接受的盐、其组合物及其使用方法
CA3109419A1 (en) Novel compounds
CN114149424A (zh) 用于治疗疾病的杂环化合物
EP3950677A1 (en) Quinolyl-containing compound and pharmaceutical composition, and use thereof
CN119365474A (zh) Stat3抑制剂的前药
JP2025504791A (ja) ヒドロキシフェニル部分を含む化合物及びその使用
HK40063807A (en) New salicylic acid derivatives, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
US12600696B2 (en) Aromatic compounds
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
US20250109154A1 (en) Lysophosphatidylserine analogue, and lysophosphatidylserine analogue-containing phamaceutical composition for treating or preventing fibrosis
JP2021521109A (ja) Ｋｅａｐ１／ｎｒｆ２タンパク質間相互作用の１，４−置換イソキノリン阻害剤
US20240293559A1 (en) SHP2 inhibitor, pharmaceutical composition containing the same and application thereof
HK1260375A1 (en) Heterocyclic compounds for the treatment of disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063807

Country of ref document: HK

CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Patrick Thomas Gonen

Inventor after: SIAVASH ahmel

Inventor after: David Rosa

Inventor after: Gary Ting

Inventor after: Mulu Gretu and Yeh

Inventor after: Pu Zhixing

Inventor after: Elvin D. de arauyo

Inventor before: Patrick Thomas Gonen

Inventor before: SIAVASH ahmel

Inventor before: David Rosa

Inventor before: Gary Ting

Inventor before: Mulu geletu

Inventor before: Pu Zhixing

Inventor before: Elvin D. de arauyo

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211116